Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04433078
Other study ID # The STORM Trial
Secondary ID
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date June 22, 2020
Est. completion date April 13, 2021

Study information

Verified date April 2021
Source Temple University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary aim of this study is to test whether Doxycycline can benefit patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections by inhibiting the replication of the virus while at the same time blocking the development of cytokine storms or inhibiting cytokine-associated coagulopathy respectively. The investigators hypothesize that Doxycycline will will improve survival and reduce morbidity in SARS-CoV-2 infected patients. A secondary aim is to identify genetic variants that predict either an unusually mild disease or an unusually severe disease - knowledge that can be used to design new and precise medications and to be able to predict patients who might get into early trouble and to therefore hospitalize them.


Description:

This study will randomize 20 patients with confirmed or highly suspected early stage severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to Doxycycline (100 mg BID) or Placebo and then assess the progression of their disease over the next three weeks with the primary endpoint being days alive and out of the hospital. The investigators will collect specimens for measurement of viral burden (nasopharyngeal luminex (SARS-CoV-2), SARS-CoV-2 serum quantitative viral load, SARS-CoV-2 IgM/IgG antibodies), markers of inflammation (WBC, ESR, TNFa, IL-1, IL-6, IL-1B), and cardiac dysfunction (CRP, pro-BNP, hsTnT). Eligibility will be based on history and physical examination findings - collated into a clinical suspicion score. The decision to enroll based on clinical suspicion score rather than confirmed SARS-CoV-2 disease is based on the variable and unacceptably high false negative rate of the nasopharyngeal PCR test for in early disease. Clinical Suspicion Score: Greater than or equal to 6/20 (at least 4 points of which must be clinical) will be eligible for enrollment. Clinical Criteria: Max 12 points - Fever (2 points) - Cough (2 points) - Dyspnea (2 points) - Chest pain (1 point) - Myalgias (1 point) - Fatigue (1 point) - GI symptoms (1 point) - Loss of Smell (1 point) - Loss of Taste (1 point) Exposure Criteria: Max 8 points - Contact with known COVID+ (2 points) - Healthcare worker -- frequent <6 feet contact for 15 minutes (2 points) - High-risk work -- supermarket, deli, transportation (2 points) - Endemic community -- prison/jail/nursing home/LTAC/SNF/rehab/homeless/homeless shelter (2 points) Genetic variants may explain why patients who are infected with SARS-CoV-2 have either a relatively benign or an inappropriately aggressive response to an infectious insult. Medications may be more or less effective in that group of patients harboring genetic variants of a disease-related protein. To better understand this, whole genome sequencing and analysis will be performed on all study patients.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date April 13, 2021
Est. primary completion date April 13, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Confirmed or highly suspected early stage severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), disease with clinical suspicion score >6/20, not requiring hospitalization - Age =18 years - Willing to sign the informed consent form - Willing to take study drug or placebo as directed for 21 days Exclusion Criteria: - Confirmed or highly suspected early stage severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), disease with clinical suspicion score >6/20, requiring hospitalization - Suspected or confirmed convalescent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), within the prior 4 weeks - Age <18 years' old - Inability to take medications orally - Inability to provide written consent - Known sensitivity/allergy to doxycycline or tetracyclines - Current use of doxycycline for another indication - Pregnancy - A known diagnosis of myasthenia gravis - History of Clostridium Difficile infection within past 12 months - Sun sensitivity - Individuals using medications which could lower doxycycline levels, including barbiturates, phenytoin, carbamazepine, warfarin - Individuals using isotretinoin

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Doxycycline
100 MG Tablet
Placebo
Placebo Tablet

Locations

Country Name City State
United States Temple University Hospital Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Temple University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time Free of Either Hospitalization, Hypoxemia, ICU Admission or Death Days Alive and Out of Hospital (Composite Endpoint) 21 days
Secondary NP SARS-CoV-2 PCR Change From Baseline of Nasopharyngeal Luminex NxTAG CoV (Positive/Negative) 21 days
Secondary SARS-CoV-2 Serum Quantitative Viral Load Change From Baseline of SARS-CoV-2 Serum Quantitative Viral Load 21 days
Secondary SARS-CoV-2 IgM/IgG Antibodies Change From Baseline of SARS-CoV-2 IgM/IgG Antibodies (Positive/Negative) 21 days
Secondary White Blood Cell Count (WBC) Change From Baseline of White Blood Count (CBC) K/mm3 21 days
Secondary Absolute Lymphocyte Count (ALC) Change From Baseline of Absolute Lymphocyte Count (ALC) K/mm3 21 days
Secondary C-Reactive Protein (CRP) Change From Baseline of C-Reactive Protein (CRP) mg/dL 21 days
Secondary N-Terminal Pro-B-Type Natriuretic Peptide (Pro-BNP) Change From Baseline of N-Terminal Pro-B-Type Natriuretic Peptide (Pro-BNP) pg/mL 21 days
Secondary High Sensitivity Troponin I (hsTnT) Change From Baseline of High Sensitivity Troponin I (hsTnT) ng/mL 21 days
Secondary Tumor Necrosis Factor Alpha (TNF-a) Change From Baseline of Tumor Necrosis Factor Alpha (TNF-a) 21 days
Secondary IL-1 Change From Baseline of IL-1 21 days
Secondary IL-1B Change From Baseline of IL-1B 21 days
Secondary IL-6 Change From Baseline of IL-6 21 days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04527471 - Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19 Phase 2
Recruiting NCT05584202 - Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants Phase 2
Completed NCT04579549 - Repeat Testing for SARS-CoV-2 N/A
Active, not recruiting NCT05547243 - A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China N/A
Recruiting NCT04747574 - Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection Phase 1
Recruiting NCT04613310 - PCR and Rapid Diagnostic Test on Saliva and Nasopharyngeal Swabs for the Detection of SARS-CoV-2 (COVID-19) N/A
Terminated NCT04447404 - DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury Phase 2
Completed NCT04515147 - A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19 Phase 2
Withdrawn NCT04388709 - Interferon Lambda Therapy for COVID-19 Phase 2
Active, not recruiting NCT05550142 - A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China N/A
Completed NCT04620798 - Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students N/A
Active, not recruiting NCT05547256 - A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China N/A
Completed NCT04561102 - Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From a COVID-19 Asymptomatic Population
Completed NCT04452604 - Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19
Completed NCT05366322 - A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults
Completed NCT04526769 - Detecting SARS-CoV-2 in Tears
Terminated NCT04958304 - Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study
Completed NCT04690413 - NOWDx Test for the Detection of Antibodies to COVID-19 N/A